Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total Neoadjuvant Treatment With Short-course Radiotherapy Versus Long-course Radiotherapy Followed by PD-L1 Inhibitor Plus Capecitabine-Oxaliplatin in Patients With Locally Advanced Rectal Cancer: a Multi-centres, Open-label, Phase 2, Randomized Controlled Trial

NCT07284992 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT07284992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Total Neoadjuvant Treatment With Short-course Radiotherapy Versus Long-course Radiotherapy Followed by PD-L1 Inhibitor Plus Capecitabine-Oxaliplatin in Patients With Locally Advanced Rectal Cancer: a Multi-centres, Open-label, Phase 2, Randomized Controlled Trial
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2025
Completion date
June 30, 2033
Enrollment
208 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced stage colorectal cancer, radiotherapy, rectal cancer